Esomeprazole 40 mg Provides Improved Intragastric Acid Control as Compared with Lansoprazole 30 mg and Rabeprazole 20 mg in Healthy Volunteers
Clive H. Wilder‐Smith, Lars Nyman, Kerstin Röhss(AstraZeneca (Sweden)), Catharina Nilsson-Pieschl(AstraZeneca (Sweden)), Ola Junghard(AstraZeneca (Sweden))
Cited by 41
Related Papers
Pharmacokinetics and pharmacodynamics of esomeprazole, the S‐isomer of omeprazole
|Alimentary Pharmacology & Therapeutics|2001|175
Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
|European Journal of Clinical Pharmacology|2000|140
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
|British Journal of Clinical Pharmacology|1998|124
Effect of Esomeprazole 40 mg vs Omeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease
|Digestive Diseases and Sciences|2002|93
Standardization of Surgical Technique in Antireflux Surgery: The LOTUS Trial Experience
|World Journal of Surgery|2008|92